Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 8026 AL 8040

Alcohol addiction and Alzheimer's disease: a molecular collision course

Chang JS, Huang HZ, Yuan M, Zhou Y, Liu D, Zhan KB, Zhu LQ.

Transl Psychiatry. 2025 Oct 17;15(1):410. doi: 10.1038/s41398-025-03619-6.

Spontaneous haemorrhage in subdural hygroma in an Alzheimer's patient on lecanemab

Watanabe M, Okochi R, Tezuka T, Ito D.

BMJ Case Rep. 2025 Jan 8;18(1):e263497. doi: 10.1136/bcr-2024-263497.

[Change of subjective cognitive decline in first-degree relatives of patients with Alzheimer's disease: results of a 15-year prospective study]

Selezneva ND, Roshchina IF, Kolykhalov IV, Gavrilova SI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(4. Vyp. 2):36-42. doi: 10.17116/jnevro202512504236.

An updated patent review of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease (2021-present)

Begines P, Fernández-Bolaños JG, López Ó.

Expert Opin Ther Pat. 2026 Feb;36(2):159-190. doi: 10.1080/13543776.2025.2602702. Epub 2025 Dec 23.

Cistanche flavonoids activate the Keap1-Nrf2-ARE signaling pathway in improving cognitive dysfunction in Alzheimer's disease: A review

Zhao R, Bai W, Tian Z, Li X, Sun R, Wang Z, Yan X, Jia J.

J Alzheimers Dis. 2025 Sep;107(2):409-420. doi: 10.1177/13872877251361053. Epub 2025 Sep 1.

Intranasal insulin for mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials

Silva AMP, Gonçalves OR, Tudella GCN, Nascimento MVS, Pereira MAOM, Nantes LAO, Fernandes JVA, Quiroga DG, Lima DVS Jr, Franco ES, Maia MBS.

Rev Neurol (Paris). 2026 Jan-Feb;182(1-2):36-48. doi: 10.1016/j.neurol.2025.11.005. Epub 2025 Dec 22.

Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis

Kandeel M, Mahmoud M.

J Alzheimers Dis. 2026 Feb;109(3):1089-1098. doi: 10.1177/13872877251404500. Epub 2025 Dec 8.

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Sköldunger A, Raket LL, Stellick CB, Spackman E, Hlávka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Brück C, Anderson R, Pemberton-Ross P, Urbich M, Jönsson L.

Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006. Epub 2024 Oct 8.

Efficacy and Safety of Escitalopram and Citalopram for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

da Silva AMP, Falcão L, Virgilio Ribeiro F, Ogasawara Donato K, Machado Magalhães PL, Nascimento MDVS, Leite M, Lee Han M, Quiroga DG, de Souza Franco E, de Sousa Maia MB.

J Geriatr Psychiatry Neurol. 2026 May;39(3):249-260. doi: 10.1177/08919887251369893. Epub 2025 Aug 22.

Efficacy and Safety of Lithium for Behavioral and Cognitive Symptoms in Alzheimer's Disease Dementia: A Systematic Review With Frequentist and Bayesian Meta-Analysis

Pereira da Silva AM, de Deus O, Ribeiro FV, Tudella GCN, Cabeça LS, Silva LL, Han ML, Franco JO, Costa JGP, Santos do Nascimento MDV, Andrade Fernandes JV, Franco ES, de Sousa Maia MB.

Am J Geriatr Psychiatry. 2026 Mar;34(3):371-385. doi: 10.1016/j.jagp.2025.10.001. Epub 2025 Oct 4.

Juxtacortical Lesion Precedes Lobar Microbleed During Anti-amyloid β Immunotherapy

Shindo A, Hirata Y, Tomimoto H.

Intern Med. 2025 Nov 15;64(22):3284-3286. doi: 10.2169/internalmedicine.5198-24. Epub 2025 May 15.

Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable

Farrar G, Weber CJ, Rabinovici GD.

J Prev Alzheimers Dis. 2025 Jan;12(1):100008. doi: 10.1016/j.tjpad.2024.100008. Epub 2025 Jan 1.

Utility, Costs and Cost-Utility of Amyloid-PET in the Diagnostic Process of Memory Clinic Patients: A Trial-Based Economic Evaluation From AMYPAD-DPMS

van Maurik IS, Altomare D, Collij LE, Caprioglio C, Moro C, Garibotto V, Demonet JF, Scheltens P, Farrer G, Gismondi R, Stephens AW, Gispert JD, Molinuevo JL, Grau-Rivera O, Edison P, Walker Z, Jessen F, Dzrezga A, Zeyen P, Payoux P, Saint-Aubert L, Delrieu J, Nordberg A, Barkhof F, Frisoni GB, Berkhof J.

Eur J Neurol. 2025 Jun;32(6):e70197. doi: 10.1111/ene.70197.

Efficacy and Safety of Exogenous Ketones in People with Mild Neurocognitive Disorder and Alzheimer's Disease: A Systematic Literature Review

Krolak-Salmon P, Swerdlow RH, Mastain T, Dive-Pouletty C, Pooley N, Kisomi M.

Nutr Rev. 2025 Mar 1;83(3):e1034-e1048. doi: 10.1093/nutrit/nuae098.

Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases

Zavarella M, Cecchetti G, Rugarli G, Ghirelli A, Bottale I, Orlandi F, Spinelli EG, Santangelo R, Caso F, Calloni SF, Vezzulli PQ, Falini A, Magnani G, Agosta F, Filippi M.

J Neurol. 2025 Jan 24;272(2):168. doi: 10.1007/s00415-025-12910-x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias